Ethyl 3-(3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl)-2-oxiranecarboxylate | 96244-68-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ethyl 3-(3-methyl-1-(3-methylbutylcarbamoyl)butylcarbamoyl)-2-oxiranecarboxylate
• 英文别名: ethyl 3-[[4-methyl-1-(3-methylbutylamino)-1-oxopentan-2-yl]carbamoyl]oxirane-2-carboxylate
• CAS: 96244-68-7
• 化学式: C₁₇H₃₀N₂O₅
• 分子量: 342.4
• InChiKey: SRVFFFJZQVENJC-UHFFFAOYSA-N

物化性质

• 沸点：
  538.0±50.0 °C(Predicted)
• 密度：
  1.102±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  24
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  97
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION
  申请人：Dyax Corp.

  公开号：EP3334343A1

  公开（公告）日：2018-06-20
• PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK
  申请人：Dyax Corp.

  公开号：EP3390439A1

  公开（公告）日：2018-10-24
• [EN] EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION<br/>[FR] TUBES DE COLLECTE DE SANG SOUS VIDE CONTENANT DES INHIBITEURS DE PROTÉASES POUR L'ÉVALUATION DE L'ACTIVATION DU SYSTÈME DE CONTACT
  申请人：DYAX CORP

  公开号：WO2017027771A1

  公开（公告）日：2017-02-16

  Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
• [EN] PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK<br/>[FR] DOSAGE DE QUANTIFICATION DE PEPTIDES PERMETTANT DE DISTINGUER ENTRE UN KININOGÈNE DE MASSE MOLÉCULAIRE ÉLEVÉE ET DE PLEINE LONGUEUR (HMWK) ET UN HMWK CLIVÉ
  申请人：DYAX CORP

  公开号：WO2017106504A1

  公开（公告）日：2017-06-22

  Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.